Vaxcyte, Inc. research snapshot
PCVX AI stock analysis currently reads Vaxcyte as a high-risk clinical-stage vaccine investment rather than an operating earnings compounder. PCVX closed at $54.08 on July 31, 2026, implying a market value of about $7.81 billion. Vaxcyte reported no product revenue, a trailing twelve-month net loss of about $946.53 million through Q1 2026, and a Q1 2026 net loss of $320.62 million, while holding about $2.74 billion in cash and investments at March 31, 2026. The central PCVX AI stock forecast question is whether the VAX-31 Phase 3 program, with OPUS-1 topline data expected in the fourth quarter of 2026, can turn broader pneumococcal coverage into an approved and commercially valuable franchise before cash burn and dilution erode per-share value. This page is informational research, not investment advice.
Current price
$54.08 close on July 31, 2026
Market cap
$7.81 billion reported, or $7.81 billion calculated from $54.08 x 144.40 million shares with a 0.0% variance
AI score
52 / 100
Rating
Speculative clinical-stage vaccine company with meaningful cash support and VAX-31 upside, but no product revenue and high Phase 3, funding, and commercialization risk
Trend status
Long-term trend remains positive above the 200-day average near $52, while short-term momentum has cooled from overbought to neutral and price trades below the 20-day average near $56.5 after a late-July pullback
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Vaxcyte is building a focused vaccine platform around broad-spectrum pneumococcal candidates and a cell-free protein synthesis process. The opportunity is large if the lead candidates work, but the business has not yet proven product revenue or commercial repeatability. | High |
| Moat | The potential moat comes from antigen design, cell-free manufacturing know-how, clinical data, patents, and a broad PCV franchise. It is not yet a proven commercial moat and can narrow if competitors match coverage, regulators require more evidence, or manufacturing is difficult. | Medium |
| Management | CEO Grant E. Pickering and President and CFO Andrew Guggenhime have funded an aggressive clinical and manufacturing buildout, including a February 2026 offering of 12.65 million shares at $50.00 per share. A July 2026 board change added John Markels as a director after Heath Lukatch retired. The central capital allocation test is whether the expanded investment in Phase 3 and production creates durable per-share value before additional equity issuance is required. | Medium |
| Financial trend | FY2025 operating expenses were $923.68 million and GAAP net loss was $766.63 million. Q1 2026 research and development expense rose to $312.78 million, net loss was $320.62 million, and operating cash use was $280.63 million. The trailing twelve-month net loss through Q1 2026 was about $946.53 million. There is no product revenue to offset the spending yet. | High |
| Valuation | At $54.08, PCVX trades at about 2.60x book value using the latest independent book value per share and has negative TTM earnings and free cash flow. A conventional P/E forecast is not meaningful, so the price mainly reflects probability-weighted pipeline value, cash, financing risk, and future commercial expectations. | High |
| Technical trend | Price sits above the 50-day average near $52.94 and the 200-day average near $52.06 but below the 20-day average near $56.48. RSI near 47 and a low stochastic reading point to cooled momentum after the July rally, so a clinical headline can overwhelm chart signals. | Medium |
| Risk level | Risk is very high. A failed or delayed Phase 3 program, an unfavorable FDA decision, manufacturing problems, weak pricing or uptake, financing at a low share price, or a competing PCV can change the thesis quickly. | High |
| AI confidence | The research is well supported for current filings, liquidity, enrollment milestones, and disclosed risks. Confidence is lower for forecast ranges because the company has negative earnings and its value depends on events that have not happened. | Medium |
| Investment certainty | Investment certainty is lower than AI confidence. Vaxcyte may hold valuable vaccine assets, but the evidence is still clinical and the stock price can respond more to trial probability and market sentiment than to current operating results. | Low |
PCVX AI stock forecast
The PCVX AI stock forecast must be read as a clinical and financing scenario map, not a point prediction. Because PCVX has negative EPS, the required P/E three-scenario calculation produces negative reference prices and is not decision-useful. The ranges below use the July 31 close and the independent analyst reference range of $67 to $163 as context, then show how a successful, delayed, or failed program could change the market narrative.
$110 to $163 scenario reference
More likely if OPUS-1 produces favorable topline data in the fourth quarter of 2026, OPUS-2 and OPUS-3 support the label and use cases in the first half of 2027, VAX-31 receives approval, manufacturing scales, and the market sees a credible path to meaningful PCV revenue without excessive dilution.
$60 to $110 scenario reference
More likely if the VAX-31 program continues to meet milestones but approval, launch, reimbursement, and manufacturing timelines remain uncertain. This case keeps the stock near the current level to the analyst average while cash burn and financing remain important variables.
$25 to $60 downside scenario reference
More likely if a Phase 3 study misses its endpoint, safety or immunogenicity concerns appear, the FDA requests more work, a competitor limits the commercial opportunity, manufacturing is delayed, or new equity is issued while the stock is weak.
PCVX AI technical analysis
PCVX AI technical analysis uses the July 31, 2026 close and the latest indexed technical snapshots available by the cutoff. Barchart places the 20-day, 50-day, and 200-day averages near $56.48, $52.94, and $52.06, while StockAnalysis shows RSI near 46.92 and average 20-day volume near 1.03 million shares. Because these indicators are not a live chart feed, they are reference levels rather than trading instructions.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $54.08 | StockAnalysis closing quote on July 31, 2026, down 3.36% for the session. The market cap page also reports the July 31 close and a $7.81 billion market value. |
| Immediate support reference | $52.06 to $52.94 | The indexed 200-day average near $52.06 and the 50-day average near $52.94 cluster here, with July swing lows near $52.47 to $52.50. A move into this area would test whether the late-July pullback is holding its structure. |
| Intermediate support reference | $48.89 to $50.67 | The June trading area held lows near $48.89 and closes near $50.67. This is a trend reference, not a guaranteed floor. |
| Near resistance reference | $56.48 to $58.21 | The 20-day average near $56.48 and the July 10 close near $58.21 cap the first upside zone. A sustained break would need volume and a favorable clinical catalyst. |
| Upper resistance reference | $60.67 to $65.00 | The July 7 close near $60.67 and the reported 52-week high near $65.00 form the upper zone. This area requires strong event-driven buying to clear. |
| Moving averages | 5-day $54.62; 20-day $56.48; 50-day $52.94; 100-day $55.00; 200-day $52.06 | Barchart indexed moving averages checked in August 2026. Exact values can move materially between checks. |
| Momentum | RSI 46.92; stochastic 14-day %K 30.06 / %D 22.34; ADX 20.47 | StockAnalysis and Barchart snapshots in August 2026 describe neutral momentum after the July rally cooled. These indicators cannot model trial outcomes. |
| Volume and volatility | Average 20-day volume about 1.03 million shares; ATR 14-day $2.52 or about 4.65%; historic volatility near 45% at 50-day | StockAnalysis and Barchart report the volume and ATR levels. Biotech event risk can create gaps larger than ordinary ATR readings. |
| Invalidation reference | Sustained close below $52.06 to $52.94 | A break below the indexed 50-day and 200-day cluster would weaken the longer-term chart structure. A clinical or financing update can invalidate technical levels immediately. |
PCVX AI trading strategy
The PCVX AI trading strategy is a rules-based research framework, not personalized advice. It should be paired with live price data, a clinical-trial calendar, SEC filings, position sizing, and a plan for overnight gaps because Phase 3 and FDA events can overwhelm ordinary stops.
Wait for a sustained move back above the $56.48 to $58.21 resistance reference with volume above the recent average, then confirm that the move is supported by a favorable VAX-31 update. A breakout without clinical or financing confirmation is only a price signal.
A failed breakout followed by a close below $55 weakens the short-term setup. A sustained close below the $52.06 to $52.94 long-term reference is a broader trend warning.
If price holds the $52.06 to $52.94 support area, monitor whether trial timelines, cash, share count, and manufacturing plans remain unchanged. The setup tests whether the pullback is technical rather than a change in clinical probability.
Do not average down only because PCVX reaches a moving average. Reassess if a trial result, regulatory request, safety signal, capital raise, or competitor update changes the thesis.
Track OPUS-1 topline data expected in the fourth quarter of 2026, OPUS-2 and OPUS-3 data expected in the first half of 2027, VAX-31 infant data expected by the end of the first half of 2027, VAX-A1 Phase 1 progress, manufacturing readiness, cash burn, and common shares outstanding.
Lower confidence if operating cash use accelerates, trial timelines slip, the company raises equity at an unfavorable price, or positive immunogenicity data fails to translate into regulatory and commercial evidence.
Investment research summary
Vaxcyte is trying to turn a cell-free protein synthesis platform into a commercial vaccine franchise. Customers would ultimately pay for approved vaccines, while the near-term economic engine is the capital market funding clinical development. The most important business question is whether broader pneumococcal coverage creates enough clinical and commercial value to displace or complement existing PCVs.
The potential moat is asset-level rather than a proven corporate moat: VAX-31 and VAX-24 have broad serotype designs, clinical data, intellectual property, manufacturing know-how, and a focused development program. There is little evidence yet for switching costs, network effects, or pricing power. The moat could widen after approval and supply scale, or narrow if competitors deliver similar coverage.
The failure paths are concentrated. A Phase 3 trial could miss, an apparently broad immune response could fail to translate into approval, manufacturing could delay launch, payers could limit uptake, or an established competitor could defend its share. Even good clinical data may not create returns if the stock already prices in a large share of the opportunity and the company must issue more stock.
Grant E. Pickering is CEO and Andrew Guggenhime is President and CFO. Management raised capital and increased investment in clinical development, manufacturing, and Phase 3 execution. The February 2026 follow-on offering added 12.65 million shares at $50.00 per share, which illustrates the tradeoff between maintaining a large cash runway and protecting existing shareholders from dilution. In July 2026 the company also refreshed its board, with John Markels joining as a Class II director after Heath Lukatch retired. The key management question is whether the spend converts into regulatory evidence and commercial readiness.
Vaccination remains a durable public-health need, and Vaxcyte identifies an approximately $8 billion global pneumococcal vaccine market in its filing. The long-term opportunity includes broader coverage for adults and infants plus possible future bacterial vaccines. The industry is attractive but regulated, manufacturing-intensive, and exposed to clinical failure, reimbursement, procurement, and competitive response.
At $54.08, the stock value is mainly a claim on future clinical and commercial outcomes. The financial rigor check found negative TTM P/E and P/FCF, about 2.60x book value, and no meaningful product-sales multiple because the company has no product revenue. Cash and investments of about $2.74 billion provide a buffer, but they are being consumed by development. A margin of safety would need to come from a high probability of approval and durable market share, neither of which is established today.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| PCVX closing price and market cap | $54.08 close on July 31, 2026; $7.81B reported market cap | StockAnalysis market-cap history and closing quote | August 3, 2026 |
| Shares outstanding | 144.40 million shares per StockAnalysis; 144,397,682 shares at March 31, 2026 per the Q1 2026 10-Q cover | StockAnalysis statistics and SEC Q1 2026 Form 10-Q | August 3, 2026 |
| Trailing twelve-month financial results | $946.53M net loss; about $1.09B operating loss; $6.88 to $6.91 diluted loss per share through Q1 2026 | StockAnalysis income statement and statistics | August 3, 2026 |
| FY2025 financial results | $766.63M GAAP net loss; $5.63 diluted loss per share; $923.68M operating expenses | SEC FY2025 Form 10-K and StockAnalysis financials | August 3, 2026 |
| Q1 2026 financial results | $320.62M net loss; $2.30 diluted loss per share; $312.78M R&D expense; $280.63M operating cash use | SEC Q1 2026 Form 10-Q | August 3, 2026 |
| Product revenue | No product revenue reported through Q1 2026 | SEC Q1 2026 Form 10-Q and StockAnalysis forecast data | August 3, 2026 |
| Q1 2026 cash and investments | $2.741B combined cash, cash equivalents, short-term investments, and long-term investments; about $1.62B net cash per StockAnalysis excluding long-term investments | SEC Q1 2026 Form 10-Q and StockAnalysis statistics | August 3, 2026 |
| VAX-31 Phase 3 program | OPUS-1 enrolled 4,049 participants; OPUS-2 enrolled 1,390; OPUS-3 enrolled 752; OPUS-1 topline data expected in Q4 2026 | Vaxcyte Q1 2026 earnings release and SEC Q1 2026 Form 10-Q | August 3, 2026 |
| VAX-A1 and manufacturing | First participant dosed in VAX-A1 Phase 1 on June 2, 2026; Lonza large-scale manufacturing facility completed | GlobeNewswire VAX-A1 release and Vaxcyte Q1 2026 earnings release | August 3, 2026 |
| Pneumococcal market context | Vaxcyte identifies an approximately $8B global pneumococcal vaccine market in its Q1 filing | SEC Q1 2026 Form 10-Q | August 3, 2026 |
| Analyst price reference | $67 low, $109 average, $110 median, and $163 high among 11 analyst targets shown by StockAnalysis | StockAnalysis forecast page using S&P Global and TipRanks data | August 3, 2026 |
| Technical snapshot | 20-day average near $56.48; 50-day average near $52.94; 200-day average near $52.06; RSI 46.92; average 20-day volume about 1.03M shares | Barchart and StockAnalysis indexed technical pages | August 3, 2026 |
| Short interest | 14.23M shares short, about 9.86% of shares outstanding, about 7.67 days to cover | StockAnalysis statistics using S&P Global data | August 3, 2026 |
This PCVX AI stock analysis is an informational research tool, not investment advice, a recommendation, or a promise of returns. Forecast ranges are scenario outputs based on available data and assumptions that can be wrong. Verify current prices, filings, clinical and regulatory updates, technical levels, tax rules, and personal suitability before making any financial decision.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
